NOVAVAX INC Cash and Restricted Cash
NOVAVAX INC (NVAX) had Cash and Restricted Cash of $196.04 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $196.04M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $232.93M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $256.05M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $283.36M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $196.04M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $232.93M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $256.05M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $283.36M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $268.98M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $278.48M 10-Q · filed 2026-05-06 | |
| 2024-12-31 | $545.29M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $588.59M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $695.56M 10-Q · filed 2025-08-06 | |
| 2024-03-31 | $495.94M 10-Q · filed 2025-05-08 | |
| 2023-12-31 | $583.81M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $666.36M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $517.94M 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $636.94M 10-Q · filed 2024-05-10 | |
| 2022-12-31 | $1.35B 10-K · filed 2026-02-26 | |
| 2022-09-30 | $1.29B 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $1.39B 10-Q · filed 2023-08-08 | |
| 2022-03-31 | $1.58B 10-Q · filed 2023-05-09 | |
| 2021-12-31 | $1.53B 10-K · filed 2025-02-27 | |
| 2021-09-30 | $1.95B 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $2.12B 10-Q · filed 2022-08-09 | |
| 2021-03-31 | $2.03B 10-Q · filed 2022-05-10 | |
| 2020-12-31 | $648.74M 10-K · filed 2024-02-28 | |
| 2020-09-30 | $401.74M 10-Q · filed 2021-11-05 | |
| 2020-06-30 | $531.57M 10-Q · filed 2021-08-05 | |
| 2020-03-31 | $187.19M 10-Q · filed 2021-05-10 | |
| 2019-12-31 | $82.18M 10-K · filed 2023-02-28 | |
| 2019-09-30 | $75.93M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $78.23M 10-Q · filed 2020-08-10 | |
| 2019-03-31 | $106.20M 10-Q · filed 2020-05-11 | |
| 2018-12-31 | $81.96M 10-K · filed 2022-03-01 | |
| 2018-09-30 | $75.04M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $99.56M 10-Q · filed 2019-08-07 | |
| 2018-03-31 | $133.84M 10-Q · filed 2019-05-02 | |
| 2017-12-31 | $135.43M 10-K · filed 2021-03-01 | |
| 2017-09-30 | $144.69M 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $123.16M 10-Q · filed 2018-08-08 | |
| 2017-03-31 | $124.87M 10-Q · filed 2018-05-09 | |
| 2016-12-31 | $179.26M 10-K · filed 2019-03-18 | |
| 2015-12-31 | $179.26M 10-K · filed 2020-03-11 | $130.49M 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |